Due to its significant role in ROS regulation, the thioredoxin (Trx) system has been an attractive therapeutic target for a number of cancers including pancreatic cancer [13], squamous cell carcinoma (SCC) [14], breast cancer [15, 16] and chronic myeloid leukemia [17–19]. This evidence concerns the gene TXN and familial pancreatic carcinoma.